Abstract:Human and murine brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions, and specific miRNA abundances are significantly and progressively altered in neurological disorders such as Alzheimer disease (AD), prion disease (PrD) and transgenic AD (Tg-AD) murine models when compared to age-matched controls. The innate-immune and pro-inflammatory, NF-kB-regulated 22-nucleotide single-stranded miRNA-146a is significantly up-regulated in parallel with the development of AD and PrD and with the onset of amyloidogenesis in several Tg-AD murine models. Here for the first time we provide evidence of significant up-regulation of miRNA-146a in amyloid-and-cytokine-stressed human neuronal-glial cells in primary co-culture and in the brains of 5xFAD mice [Tg(APPSwFlLon,PSEN1*M146L *L286V)6799Vas] which bear 5 (APP695+PSEN1) mutations that strongly drive the generation of Aβ42 peptides. AAV-miRNA vectors, microRNA analysis, 5xFAD Tg-AD models, RNA sequencing, RT-PCR, LED-Northern, microfluidic and bioinformatics technologies. Using stereotactic bilateral hippocampal injection of a scrambled AAV-miRNA-146a vector into 5xFAD brains as a baseline, selective AAV-miRNA-146a sponging vectors delivered into the hippocampus of 5xFAD mice exhibited (i) decreases in host miRNA-146a expression; (ii) increases in expression of the complement control glycoprotein complement factor H (CFH); (iii) decreases in BACE1, sAPPβsw and the generation of Aβ42 peptides; (iv) decreases in the expression of inflammatory and microglial markers including cyclooxygenase-2 (COX-2), glial fibrillary acidic protein (GFAP) and Iba1; (v) increased expression of the synaptic markers SYN1 and NR2B; and (vi) a significant improvement in cognitive performance in maze tests (NOR and Y-maze). Collectively, the results suggest that the implementation of a novel therapeutic strategy involving the sponging of miRNA-146a and related pro-inflammatory, pathogenic miRNAs may be useful in the effective treatment of AD and other progressive, age-related neurological disorders. Support: Research on miRNA in the Lukiw laboratory involving the innate-immune response in AD, AMD and in other forms of neurological or retinal disease, amyloidogenesis and neuro-inflammation was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and grants from the NIH NEI and NIA.

Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q

Aging-dependent loss of functional connectivity in a mouse model of Alzheimer's disease and reversal by mGluR5 modulator

Aging-Dependent Loss of Connectivity in Alzheimer’s Model Mice with Rescue by mGluR5 Modulator

Activation of Mglur1 Mediates C1q-Dependent Microglial Phagocytosis of Glutamatergic Synapses in Alzheimer’s Rodent Models

C5aR1 signaling promotes region‐ and age‐dependent synaptic pruning in models of Alzheimer's disease

Repetitive Transcranial Magnetic Stimulation-Mediated Neuroprotection in the 5xFAD Mouse Model of Alzheimer's Disease Through GABRG2 and SNAP25 Modulation

A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model

C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer's disease mouse model

Microglial deletion of C1q rescues AD cognitive decline and synaptic loss

Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel Mglu5 Positive Allosteric Modulator.

Conditional knockout of AIM2 in microglia ameliorates synaptic plasticity and spatial memory deficits in a mouse model of Alzheimer's disease

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Prodromal Glutamatergic Modulation with Riluzole Impacts Glucose Homeostasis and Spatial Cognition in Alzheimer's Disease Mice

Microglial repopulation reverses cognitive and synaptic deficits in an Alzheimer's disease model by restoring BDNF signaling

Chronic potentiation of metabotropic glutamate receptor 2 with a nanobody accelerates amyloidogenesis in Alzheimer’s disease

Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer's disease: A [18F]PSS232 PET/MRI study

Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer’s Disease

Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Sponging of mirna-146a using aav-anti-mirna-146a-vectors mediates synaptic and amyloidogenic neuropathology and cognitive deficits in a 5xfad murine model of alzheimer’s disease